{"gene":"SLC22A3","run_date":"2026-06-10T07:46:32","timeline":{"discoveries":[{"year":2001,"finding":"Genetic knockout of mouse Orct3/Slc22a3 demonstrated that this transporter is the principal component of the extraneuronal uptake-2 system in the adult heart, as measured by a 72% reduction in intravenously administered [3H]MPP+ accumulation in hearts of null mice. Additionally, Orct3 was identified as functioning at the fetoplacental interface, with a threefold-reduced MPP+ accumulation in homozygous mutant embryos but not in placentas.","method":"Homologous recombination knockout mouse model; isotopic [3H]MPP+ uptake assays in vivo","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vivo loss-of-function with quantitative substrate accumulation assays, replicated across sexes and developmental stages","pmids":["11390648"],"is_preprint":false},{"year":1999,"finding":"SLC22A3 was cloned and mapped to human chromosome 6q26-q27 in a conserved cluster with SLC22A1 and SLC22A2. Expression was detected in placenta (first-trimester and term), skeletal muscle, prostate, aorta, liver, fetal lung, salivary gland, and adrenal gland.","method":"cDNA cloning from EST clones; Northern blot expression analysis; somatic cell hybrid panel mapping; YAC clone mapping","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct cloning and localization by multiple methods in a single study","pmids":["9933568"],"is_preprint":false},{"year":2001,"finding":"Slc22a3/Orct3 co-localizes with the monoamine-metabolizing enzyme Maoa in the labyrinth layer of mouse placenta, establishing that these two components of monoamine clearance are co-expressed at the same site, distinct from neuronal transporter expression patterns.","method":"RNA blot analysis; in situ hybridization in mouse embryo placenta sections","journal":"Mechanisms of development","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — direct localization by two orthogonal methods (RNA blot + ISH) in a single lab","pmids":["11118898"],"is_preprint":false},{"year":2003,"finding":"Imprinted silencing of Slc22a3 (paternal allele) does not require transcriptional overlap between Igf2r and the non-coding Air RNA; silencing is maintained even when the Igf2r promoter is replaced by a heterologous promoter or deleted entirely.","method":"Genetic epistasis using knock-in mice with replaced or deleted Igf2r promoter; allele-specific expression analysis","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — genetic epistasis with multiple allelic combinations tested, mechanistically defining cis-regulatory requirements for imprinting","pmids":["12853484"],"is_preprint":false},{"year":2005,"finding":"hOCT3 (SLC22A3) mediates uptake of organic cations with substrate selectivity distinct from hOCT1 and hOCT2: famotidine is a potent inhibitor of hOCT3 (IC50 = 6.7 µM) while ranitidine is a weak inhibitor (IC50 = 290 µM); no stimulation of [3H]ranitidine uptake was detected in hOCT3-expressing oocytes, indicating ranitidine is not an hOCT3 substrate.","method":"Xenopus laevis oocyte expression system; isotopic uptake inhibition assays; trans-stimulation; electrophysiology","journal":"The Journal of pharmacology and experimental therapeutics","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted transport in heterologous expression system with multiple orthogonal methods (uptake inhibition, trans-stimulation, electrophysiology)","pmids":["16141367"],"is_preprint":false},{"year":2008,"finding":"hOCT3/SLC22A3 transports oxaliplatin (but not cisplatin) into colorectal cancer cells, mediating cytotoxicity: transfection of hOCT3 into SW480 cells increased platinum accumulation and LDH release after oxaliplatin treatment; colorectal cancer cell lines with high endogenous hOCT3 accumulated more platinum and showed greater cytotoxicity.","method":"cDNA transfection; LDH release cytotoxicity assay; ICP-MS platinum accumulation measurement; qRT-PCR mRNA quantification","journal":"Drug metabolism and disposition","confidence":"High","confidence_rationale":"Tier 1 / Moderate — functional reconstitution by transfection plus orthogonal cytotoxicity and platinum accumulation assays in multiple cell lines","pmids":["18710896"],"is_preprint":false},{"year":2009,"finding":"OCT3/SLC22A3 protein is localized to the basolateral membrane of hepatocytes, and metformin is confirmed as an OCT3 substrate by isotopic uptake studies in transfected cells.","method":"Immunofluorescence microscopy for subcellular localization; isotopic uptake assays in transfected cells","journal":"Hepatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization by immunofluorescence plus functional substrate confirmation in transfected cells, single lab","pmids":["19591196"],"is_preprint":false},{"year":2010,"finding":"OCT3/SLC22A3 plays a role in metformin's pharmacological action: OCT3 is expressed on the plasma membrane of skeletal muscle and liver (metformin target tissues); OCT inhibitor cimetidine and OCT3-specific shRNA significantly reduced metformin-induced AMP-activated protein kinase activation. Three missense variants (T44M, T400I, V423F) showed altered substrate specificity for metformin and catecholamines in functional assays.","method":"Quantitative PCR; immunostaining; isotopic uptake assays in transfected cells; shRNA knockdown; AMPK phosphorylation assay; structural modeling","journal":"Pharmacogenetics and genomics","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple orthogonal methods (shRNA KD, pharmacologic inhibition, isotopic uptake, AMPK assay) converging on same conclusion in one study","pmids":["20859243"],"is_preprint":false},{"year":2010,"finding":"Three OCT3 missense variants (A116S, T400I, A439V) show reduced uptake of both [3H]histamine and [3H]MPP+ despite normal plasma membrane localization, indicating these variants impair transport activity without affecting trafficking.","method":"Transient transfection; isotopic uptake assays; immunostaining for protein localization","journal":"Journal of pharmacological sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — functional isotopic uptake assay with localization control, single lab, single paper","pmids":["20562519"],"is_preprint":false},{"year":2012,"finding":"The SLC22A3 promoter is regulated by epigenetic methylation (associated with reduced expression in prostate cancer) and by genetic variants: haplotypes containing g.-81G>delGA and g.-2G>A show increased luciferase reporter activity and stronger transcription factor binding affinity; the g.-2A allele correlates with higher OCT3 mRNA in liver.","method":"Luciferase reporter assay; electrophoretic mobility shift assay; bisulfite sequencing; mRNA expression analysis in human liver samples","journal":"The pharmacogenomics journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple functional assays (reporter, EMSA, methylation analysis, expression correlation) in a single lab","pmids":["22231567"],"is_preprint":false},{"year":2012,"finding":"Oct3/Slc22a3 is localized on the basolateral (fetus-facing) side of rat placental trophoblast, and together with apically-localized Mate1/Slc47a1, forms an efficient transplacental eliminatory pathway: Oct3 takes up MPP+ from fetal circulation into the placenta, while Mate1 effluxes it to the maternal side, transporting substrate against a concentration gradient.","method":"qRT-PCR; Western blot; immunohistochemistry; in situ dually perfused rat term placenta (open- and closed-circuit); [3H]MPP+ transport assays","journal":"Toxicological sciences","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct functional localization plus reconstituted transplacental transport with pharmacologic inhibition, multiple experimental configurations","pmids":["22543277"],"is_preprint":false},{"year":2013,"finding":"OCT3/SLC22A3 mediates the fetal-to-maternal transplacental transfer of metformin in rat placenta in a concentration-dependent manner; this transport is completely inhibited by MPP+ and is driven by opposing H+ gradient for MATE1-mediated efflux, confirming functional coupling of OCT3 (basolateral uptake) and MATE1 (apical efflux) in metformin secretion.","method":"Dually perfused rat term placenta model; pharmacologic inhibition with MPP+; pH gradient manipulation","journal":"Reproductive toxicology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct functional reconstitution in intact perfused placenta with pharmacologic dissection, builds on prior work by same group","pmids":["23562376"],"is_preprint":false},{"year":2015,"finding":"The transcription factor Pet-1 controls expression of Slc22a3 in serotonin neurons: comparative microarray profiling of flow-sorted Pet-1-/- versus wild-type 5-HT neurons showed loss of Slc22a3 expression; in situ hybridization confirmed that virtually all 5-HT neurons in the dorsal raphe depend on Pet-1 for Slc22a3 expression, establishing Pet-1 as a transcriptional regulator coordinating both 5-HT synthesis and reuptake genes.","method":"Comparative microarray of flow-sorted YFP+ neurons; in situ hybridization","journal":"ACS chemical neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — microarray plus orthogonal ISH validation, loss-of-function genetic model, single lab","pmids":["25642596"],"is_preprint":false},{"year":2017,"finding":"A-to-I RNA editing of SLC22A3 mRNA by ADAR2 results in reduced SLC22A3 expression in non-tumor esophageal tissues. SLC22A3 acts as a metastasis suppressor: it directly associates with α-actinin-4 (ACTN4), and loss of this interaction increases ACTN4 actin-binding activity, facilitating cell invasion and filopodia formation.","method":"Co-immunoprecipitation (SLC22A3–ACTN4 interaction); actin-binding activity assay; cell invasion assays; filopodia formation imaging; RNA editing quantification; shRNA knockdown","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct binding partner identified by Co-IP, functional consequence demonstrated by actin-binding and invasion assays with mechanistic pathway defined","pmids":["28533408"],"is_preprint":false},{"year":2019,"finding":"Oncogenic PITX2 transcription factor represses SLC22A3/hOCT3 expression: ChIP-qPCR showed PITX2 binds the hOCT3/SLC22A3 promoter in colon and renal cancer cells; PITX2 siRNA knockdown increased hOCT3/SLC22A3 expression and activity and reverted vincristine resistance, while heterologous PITX2 overexpression suppressed hOCT3/SLC22A3 and enhanced drug resistance. PITX2A and PITX2C isoforms were most effective.","method":"ChIP-qPCR; siRNA knockdown; heterologous overexpression; drug resistance/viability assays; transporter activity assays","journal":"Cancer letters","confidence":"High","confidence_rationale":"Tier 1 / Moderate — ChIP-qPCR for direct promoter binding plus bidirectional functional manipulation (siRNA KD and overexpression) with functional consequence","pmids":["30742940"],"is_preprint":false},{"year":2020,"finding":"OCT3/SLC22A3 is localized on the fetus-facing membrane of syncytiotrophoblast in human and rat term placenta, where it massively takes up serotonin from fetal circulation in a concentration-dependent and OCT3 blocker-inhibitable manner, forming a protective mechanism against local vasoconstriction with MAO-A. Glucocorticoids and antidepressants can inhibit this system.","method":"Dually perfused rat term placenta; placental membrane vesicles from human term placenta; pharmacologic inhibition with OCT3 blockers (glucocorticoids, pharmaceuticals); concentration-response analysis","journal":"Acta physiologica","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct functional transport assays in intact perfused organ and isolated membrane vesicles with pharmacologic dissection, two species","pmids":["32311818"],"is_preprint":false},{"year":2020,"finding":"The SLC22A3 promoter variant -1603G>A reduces p53 binding to the promoter region, leading to decreased SLC22A3 mRNA expression in human skin; homozygous -1603A/A individuals have significantly lower SLC22A3 mRNA levels and lower squalene levels in skin, linking OCT3 to sebaceous gland function.","method":"Immunohistochemistry; luciferase reporter assay; ChIP; electrophoretic mobility shift assay (EMSA); mRNA expression analysis; in vivo sebum/squalene measurement","journal":"Journal of dermatological science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple functional assays (reporter, ChIP, EMSA) plus in vivo phenotypic correlation, single lab","pmids":["33168399"],"is_preprint":false},{"year":2022,"finding":"AR-V7/YAP1/TAZ axis represses SLC22A3 in enzalutamide-resistant castration-resistant prostate cancer: YAP1/TAZ hyperactivated by AR full-length or AR-V7 interacts with DNMT1 to methylate and silence the SLC22A3 promoter; this repression was demonstrated in ENZ-resistant C4-2B MDVR cells.","method":"Co-immunoprecipitation (YAP1/TAZ–DNMT1 interaction); siRNA knockdown; promoter methylation analysis; Western blot; immunostaining in patient tissues","journal":"The FEBS journal","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — Co-IP for complex identification plus functional methylation evidence, single lab, single paper","pmids":["36254631"],"is_preprint":false},{"year":2023,"finding":"Neuronal activity induces Slc22a3 expression in astrocytes; loss of astrocytic Slc22a3 reduces intracellular serotonin levels, leading to decreased histone serotonylation in astrocytes, reduced GABA biosynthetic gene expression, reduced GABA release, and olfactory sensory processing deficits in mice.","method":"Activity-inducible gene expression profiling; conditional knockout (loss-of-function) with behavioral phenotyping; serotonin quantification; histone serotonylation assay; GABA release measurement; olfactory bulb circuit analysis","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean conditional KO with specific cellular phenotype, multiple orthogonal downstream measurements (histone serotonylation, GABA biosynthesis, GABA release, behavioral), peer-reviewed in high-impact journal","pmids":["37319217"],"is_preprint":false},{"year":2022,"finding":"Tammar wallaby SLC22A3 is imprinted (paternal allele silenced) specifically in placental tissue, with the protein localized to the endodermal cell layer where nutrient trafficking occurs; promoter lacks DNA methylation, indicating silencing is not via direct DMR at the SLC22A3 promoter as in mouse.","method":"Allele-specific expression analysis; bisulfite sequencing; immunofluorescence localization in tammar wallaby placenta","journal":"Epigenetics & chromatin","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — allele-specific expression plus methylation analysis and direct protein localization, mechanistically defining imprinting mechanism in a marsupial","pmids":["36030241"],"is_preprint":false},{"year":2012,"finding":"SLC22A3 suppression reduces tumor-related cellular phenotypes (proliferation, migration, invasion) in prostate cancer cells, implicating SLC22A3 in prostate cancer pathogenesis through functional cellular assays.","method":"siRNA knockdown of SLC22A3 in prostate cancer cell lines; assays for proliferation, migration, and invasion","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — functional KD phenotype in cell lines, single lab, abstract does not provide full mechanistic detail","pmids":["22730461"],"is_preprint":false},{"year":2018,"finding":"SLC22A3 acts as an antioxidant gene in normal esophageal epithelial cells: deregulation of SLC22A3 (by promoter hypermethylation) facilitates heat stress-induced oxidative DNA damage and formation of γ-H2AX foci.","method":"Bisulfite sequencing for promoter methylation; γ-H2AX foci immunofluorescence after heat stress; functional overexpression/knockdown","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct functional consequence of SLC22A3 loss on oxidative DNA damage, single lab, limited mechanistic detail in abstract","pmids":["30416380"],"is_preprint":false},{"year":2026,"finding":"SLC22A3/OCT3 regulates pancreatic cancer stem cell (CSC) stemness through serotonin transport: SLC22A3 is upregulated in CSC-enriched populations; its silencing in 2D cultures and 3D organoid models reduces stemness features; serotonin transport by SLC22A3 enhances stemness via downstream histone modifications.","method":"siRNA silencing; 2D cell culture and 3D organoid models; stemness assays; histone modification analysis","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function in 2D and 3D models with downstream histone modification readout, single lab, single paper","pmids":["42250222"],"is_preprint":false},{"year":2026,"finding":"Cardiac SLC22A3 deficiency in heart failure leads to elevated peripheral and brain histamine levels; cardiac-specific SLC22A3 overexpression reduces histamine accumulation, preserves blood-brain barrier integrity, and improves cognitive performance. Mechanistically, elevated histamine activates hippocampal microglial H1R/NLRP3 inflammasome signaling to drive neuroinflammation; blocking H1R or NLRP3 in hippocampus rescues heart failure-induced cognitive impairment.","method":"Mouse MI model; cardiac-specific SLC22A3 overexpression; hippocampal-specific H1R knockdown; NLRP3 knockout mice; BV2 cell assays; Morris water maze; immunofluorescence; Western blot","journal":"Redox biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple genetic manipulations (OE, KD, KO) with converging mechanistic pathway, single lab","pmids":["41833108"],"is_preprint":false}],"current_model":"SLC22A3 (OCT3) is a polyspecific organic cation transporter localized to basolateral membranes of hepatocytes, the fetus-facing membrane of placental syncytiotrophoblast, and plasma membranes of skeletal muscle, heart, and other tissues, where it mediates electrogenic, facilitated uptake of monoamines (noradrenaline, dopamine, serotonin, histamine), cationic drugs (metformin, oxaliplatin, MPP+), and other organic cations; in the heart it is the principal component of the extraneuronal uptake-2 system; in placenta it forms a vectorial transport axis with MATE1 to protect the fetus from xenobiotics and regulate serotonin homeostasis; in astrocytes, activity-induced Slc22a3 expression drives serotonin uptake, histone serotonylation, GABA release, and sensory processing; in cancer cells it acts as a metastasis suppressor by binding α-actinin-4 (ACTN4) and is epigenetically silenced by promoter methylation, PITX2-mediated transcriptional repression, or AR-V7/YAP1/TAZ–DNMT1 complexes; paternal allele silencing in placenta is controlled in cis by the Air non-coding RNA independently of Igf2r transcriptional overlap; and genetic variants in its coding and promoter regions alter substrate transport kinetics and drug response."},"narrative":{"mechanistic_narrative":"SLC22A3 (OCT3) is a polyspecific, electrogenic organic cation transporter that mediates facilitated uptake of monoamines and cationic drugs across plasma membranes in heart, liver, placenta, skeletal muscle, and the nervous system, and constitutes the principal extraneuronal uptake-2 system of the adult heart [PMID:11390648, PMID:16141367]. Its substrate spectrum—distinct from the related OCT1/OCT2 transporters with which it clusters on chromosome 6q26-q27—includes MPP+, histamine, serotonin, the cytotoxic platinum drug oxaliplatin, and metformin, the last of which it carries into target tissues to drive AMPK activation [PMID:9933568, PMID:16141367, PMID:18710896, PMID:19591196, PMID:20859243]. In the placenta OCT3 resides on the fetus-facing (basolateral) membrane of the trophoblast and operates as the uptake arm of a vectorial elimination axis with the apical efflux transporter MATE1, clearing organic cations and serotonin from the fetal circulation; co-expression with the monoamine-metabolizing enzyme MAO-A makes this a combined detoxification and serotonin-homeostasis system [PMID:11118898, PMID:22543277, PMID:23562376, PMID:32311818]. The gene is subject to genomic imprinting with paternal-allele silencing in placenta, maintained in cis independently of Igf2r/Air transcriptional overlap [PMID:12853484]. In the brain, activity-induced astrocytic SLC22A3 imports serotonin to fuel histone serotonylation, GABA biosynthesis, and sensory processing, while cardiac OCT3 loss elevates histamine to drive H1R/NLRP3-dependent neuroinflammation and cognitive impairment [PMID:37319217, PMID:41833108]. In epithelial cancers SLC22A3 functions as a metastasis suppressor by binding α-actinin-4 (ACTN4) to restrain its actin-binding and invasive activity, and is silenced through promoter hypermethylation, PITX2-mediated repression, and an AR-V7/YAP1/TAZ–DNMT1 axis [PMID:28533408, PMID:30742940, PMID:36254631, PMID:22730461]. Coding and promoter variants of SLC22A3 alter transport kinetics, transcription-factor binding, and downstream drug response and tissue phenotypes [PMID:20859243, PMID:20562519, PMID:22231567, PMID:33168399].","teleology":[{"year":1999,"claim":"Establishing the gene's identity, chromosomal location, and tissue distribution defined SLC22A3 as a third member of an organic-cation transporter cluster with broad somatic expression.","evidence":"cDNA cloning, Northern blot, and somatic-cell-hybrid/YAC mapping","pmids":["9933568"],"confidence":"Medium","gaps":["No transport function demonstrated in this study","Subcellular localization not resolved"]},{"year":2001,"claim":"Knockout of the mouse ortholog answered whether OCT3 carries a defined physiological transport burden in vivo, identifying it as the principal extraneuronal uptake-2 system of the heart and a fetoplacental transporter.","evidence":"Homologous-recombination knockout mouse with in vivo [3H]MPP+ accumulation assays; placental ISH co-localization with Maoa","pmids":["11390648","11118898"],"confidence":"High","gaps":["Endogenous physiological substrate(s) in heart not pinned to a single monoamine","Mechanism of membrane targeting not addressed"]},{"year":2003,"claim":"Genetic epistasis defined the cis-regulatory logic of SLC22A3 imprinting, showing paternal silencing does not require Igf2r/Air transcriptional overlap.","evidence":"Knock-in mice with replaced or deleted Igf2r promoter and allele-specific expression analysis","pmids":["12853484"],"confidence":"High","gaps":["The Air-dependent silencing mechanism (chromatin vs. RNA-mediated) not fully resolved","Does not address human imprinting status"]},{"year":2008,"claim":"Substrate-selectivity and drug-transport studies established OCT3 as a distinct organic-cation carrier handling specific therapeutics including oxaliplatin and famotidine.","evidence":"Xenopus oocyte uptake/electrophysiology and cancer-cell transfection with ICP-MS platinum accumulation and cytotoxicity assays","pmids":["16141367","18710896"],"confidence":"High","gaps":["Structural basis of substrate selectivity not determined","In vivo relevance of oxaliplatin transport not tested"]},{"year":2010,"claim":"Linking OCT3 to metformin action and characterizing coding variants connected transport activity to pharmacological outcome and inter-individual variation.","evidence":"shRNA knockdown, pharmacologic inhibition, isotopic uptake, AMPK assays, and variant uptake assays with localization controls","pmids":["20859243","20562519","19591196"],"confidence":"High","gaps":["Whether variants alter clinical metformin response not established","Hepatic basolateral targeting mechanism unknown"]},{"year":2012,"claim":"Dual perfusion of placenta and identification of neuronal/cancer regulators showed OCT3 forms a vectorial transplacental elimination axis with MATE1 and is transcriptionally controlled in specialized cell types.","evidence":"Dually perfused rat placenta with pharmacologic dissection; Pet-1 knockout microarray/ISH in 5-HT neurons; promoter reporter/EMSA/methylation analyses; prostate cancer siRNA phenotyping","pmids":["22543277","22231567","22730461","25642596"],"confidence":"High","gaps":["Whether placental coupling operates identically in human in vivo not fully proven","Direct transcription factors driving promoter haplotype effects not all identified"]},{"year":2013,"claim":"Demonstration that OCT3 carries metformin fetal-to-maternal against gradient confirmed functional coupling of basolateral OCT3 uptake with apical MATE1 efflux.","evidence":"Dually perfused rat placenta with MPP+ inhibition and pH-gradient manipulation","pmids":["23562376"],"confidence":"High","gaps":["Quantitative contribution to human fetal drug exposure unmeasured"]},{"year":2017,"claim":"Identification of the SLC22A3–ACTN4 interaction provided a transport-independent mechanism for its metastasis-suppressor function.","evidence":"Co-IP, actin-binding and invasion/filopodia assays, RNA-editing quantification, and shRNA knockdown in esophageal cancer","pmids":["28533408"],"confidence":"High","gaps":["Whether ACTN4 binding requires transport activity unresolved","Structural details of the interaction not defined"]},{"year":2019,"claim":"PITX2 was defined as a direct transcriptional repressor of SLC22A3 governing chemoresistance.","evidence":"ChIP-qPCR, bidirectional siRNA/overexpression, and drug-resistance/transporter-activity assays in colon and renal cancer cells","pmids":["30742940"],"confidence":"High","gaps":["Cofactors recruited by PITX2 at the promoter not identified","Relationship to methylation-based silencing not integrated"]},{"year":2020,"claim":"Placental serotonin-clearance and skin-phenotype studies extended OCT3's physiological roles to fetal serotonin homeostasis and sebaceous gland function, with promoter p53 binding as a regulatory input.","evidence":"Dually perfused rat placenta and human membrane vesicles with pharmacologic inhibition; promoter ChIP/EMSA/reporter and in vivo squalene measurement","pmids":["32311818","33168399"],"confidence":"High","gaps":["Causal link between OCT3 serotonin uptake and placental vascular outcomes not directly demonstrated in human pregnancy","Skin phenotype based on variant correlation"]},{"year":2022,"claim":"Comparative imprinting and additional cancer-silencing studies showed the imprinting mechanism differs across mammals and that an AR-V7/YAP1/TAZ–DNMT1 axis methylates SLC22A3 in resistant prostate cancer.","evidence":"Marsupial allele-specific expression/bisulfite/localization; Co-IP, siRNA, and promoter methylation analysis in enzalutamide-resistant prostate cancer cells","pmids":["36030241","36254631"],"confidence":"Medium","gaps":["Marsupial silencing mechanism without promoter DMR not mechanistically defined","AR-V7/YAP1/TAZ–DNMT1 model rests on single-lab Co-IP"]},{"year":2023,"claim":"Astrocytic conditional knockout connected OCT3 serotonin import to histone serotonylation and GABAergic signaling, establishing a role in sensory circuit function.","evidence":"Activity-inducible profiling, conditional KO with behavioral phenotyping, serotonin/serotonylation and GABA-release measurements in olfactory bulb","pmids":["37319217"],"confidence":"High","gaps":["Whether this pathway operates in human brain unknown","Generality beyond olfactory circuitry untested"]},{"year":2026,"claim":"Cardiac and cancer-stem-cell studies tied OCT3 substrate transport to histamine-driven neuroinflammation and serotonin-dependent stemness via histone modifications.","evidence":"Mouse MI model with cardiac OCT3 overexpression and hippocampal H1R knockdown/NLRP3 KO; siRNA silencing in 2D and 3D pancreatic cancer organoid models with histone-modification readouts","pmids":["41833108","42250222"],"confidence":"Medium","gaps":["Heart-to-brain histamine axis demonstrated only in mouse","Direct histone-modification enzymology downstream of OCT3 transport not defined"]},{"year":null,"claim":"How OCT3's transport activity is mechanistically coupled to its non-transport scaffolding/suppressor roles, and how a single transporter's substrate flux is translated into chromatin (serotonylation, histone-modification) outputs across tissues, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structure of human OCT3 reported in the corpus","Mechanism linking cation uptake to histone serotonylation enzymology undefined","Whether ACTN4 binding and transport are separable functions unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005215","term_label":"transporter activity","supporting_discovery_ids":[0,4,5,6,10,15]},{"term_id":"GO:0140104","term_label":"molecular carrier activity","supporting_discovery_ids":[4,6,15]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[13]},{"term_id":"GO:0016209","term_label":"antioxidant activity","supporting_discovery_ids":[21]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[6,7,8,10,15]}],"pathway":[{"term_id":"R-HSA-382551","term_label":"Transport of small molecules","supporting_discovery_ids":[0,4,10,11,15]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[13,14,17,20]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[12,18]}],"complexes":[],"partners":["ACTN4","SLC47A1","MATEINTERACTION"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O75751","full_name":"Solute carrier family 22 member 3","aliases":["Extraneuronal monoamine transporter","EMT","Organic cation transporter 3","OCT3"],"length_aa":556,"mass_kda":61.3,"function":"Electrogenic voltage-dependent transporter that mediates the transport of a variety of organic cations such as endogenous bioactive amines, cationic drugs and xenobiotics (PubMed:10196521, PubMed:10966924, PubMed:12538837, PubMed:17460754, PubMed:20858707). Cation cellular uptake or release is driven by the electrochemical potential, i.e. membrane potential and concentration gradient (PubMed:10966924). Functions as a Na(+)- and Cl(-)-independent, bidirectional uniporter (PubMed:12538837). Implicated in monoamine neurotransmitters uptake such as dopamine, adrenaline/epinephrine, noradrenaline/norepinephrine, histamine, serotonin and tyramine, thereby supporting a role in homeostatic regulation of aminergic neurotransmission in the brain (PubMed:10196521, PubMed:16581093, PubMed:20858707). Transports dopaminergic neuromodulators cyclo(his-pro) and salsolinol with low efficiency (PubMed:17460754). May be involved in the uptake and disposition of cationic compounds by renal clearance from the blood flow (PubMed:10966924). May contribute to regulate the transport of cationic compounds in testis across the blood-testis-barrier (Probable). Mediates the transport of polyamine spermidine and putrescine (By similarity). Mediates the bidirectional transport of polyamine agmatine (PubMed:12538837). Also transports guanidine (PubMed:10966924). May also mediate intracellular transport of organic cations, thereby playing a role in amine metabolism and intracellular signaling (By similarity)","subcellular_location":"Cell membrane; Apical cell membrane; Basolateral cell membrane; Mitochondrion membrane; Endomembrane system; Nucleus membrane; Nucleus outer membrane","url":"https://www.uniprot.org/uniprotkb/O75751/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SLC22A3","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SLC22A3","total_profiled":1310},"omim":[{"mim_id":"612276","title":"YRDC DOMAIN-CONTAINING PROTEIN; YRDC","url":"https://www.omim.org/entry/612276"},{"mim_id":"604893","title":"ANTISENSE IGF2R RNA, NONCODING; AIRN","url":"https://www.omim.org/entry/604893"},{"mim_id":"604842","title":"SOLUTE CARRIER FAMILY 22 (EXTRANEURONAL MONOAMINE TRANSPORTER), MEMBER 3; SLC22A3","url":"https://www.omim.org/entry/604842"},{"mim_id":"604599","title":"EUCHROMATIC HISTONE-LYSINE N-METHYLTRANSFERASE 2; EHMT2","url":"https://www.omim.org/entry/604599"},{"mim_id":"602608","title":"SOLUTE CARRIER FAMILY 22 (ORGANIC CATION TRANSPORTER), MEMBER 2; SLC22A2","url":"https://www.omim.org/entry/602608"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"blood vessel","ntpm":77.1}],"url":"https://www.proteinatlas.org/search/SLC22A3"},"hgnc":{"alias_symbol":["OCT3","EMT"],"prev_symbol":[]},"alphafold":{"accession":"O75751","domains":[{"cath_id":"1.20.1250.20","chopping":"2-52_139-331","consensus_level":"medium","plddt":88.0893,"start":2,"end":331},{"cath_id":"1.20.1250.20","chopping":"337-537","consensus_level":"medium","plddt":87.3869,"start":337,"end":537}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O75751","model_url":"https://alphafold.ebi.ac.uk/files/AF-O75751-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O75751-F1-predicted_aligned_error_v6.png","plddt_mean":83.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SLC22A3","jax_strain_url":"https://www.jax.org/strain/search?query=SLC22A3"},"sequence":{"accession":"O75751","fasta_url":"https://rest.uniprot.org/uniprotkb/O75751.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O75751/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O75751"}},"corpus_meta":[{"pmid":"19198611","id":"PMC_19198611","title":"Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease.","date":"2009","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19198611","citation_count":362,"is_preprint":false},{"pmid":"19591196","id":"PMC_19591196","title":"Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver.","date":"2009","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/19591196","citation_count":308,"is_preprint":false},{"pmid":"20859243","id":"PMC_20859243","title":"Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin.","date":"2010","source":"Pharmacogenetics and genomics","url":"https://pubmed.ncbi.nlm.nih.gov/20859243","citation_count":162,"is_preprint":false},{"pmid":"11390648","id":"PMC_11390648","title":"Impaired activity of the extraneuronal monoamine transporter system known as uptake-2 in Orct3/Slc22a3-deficient mice.","date":"2001","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11390648","citation_count":147,"is_preprint":false},{"pmid":"9933568","id":"PMC_9933568","title":"Cloning of the mouse and human solute carrier 22a3 (Slc22a3/SLC22A3) identifies a conserved cluster of three organic cation transporters on mouse chromosome 17 and human 6q26-q27.","date":"1999","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9933568","citation_count":96,"is_preprint":false},{"pmid":"22730461","id":"PMC_22730461","title":"Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis.","date":"2012","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/22730461","citation_count":90,"is_preprint":false},{"pmid":"28533408","id":"PMC_28533408","title":"RNA editing of SLC22A3 drives early tumor invasion and metastasis in familial esophageal cancer.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/28533408","citation_count":85,"is_preprint":false},{"pmid":"16141367","id":"PMC_16141367","title":"Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3).","date":"2005","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/16141367","citation_count":83,"is_preprint":false},{"pmid":"18710896","id":"PMC_18710896","title":"Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer.","date":"2008","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/18710896","citation_count":82,"is_preprint":false},{"pmid":"12853484","id":"PMC_12853484","title":"Imprinted silencing of Slc22a2 and Slc22a3 does not need transcriptional overlap between Igf2r and Air.","date":"2003","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/12853484","citation_count":73,"is_preprint":false},{"pmid":"22231567","id":"PMC_22231567","title":"Genetic and epigenetic regulation of the organic cation transporter 3, SLC22A3.","date":"2012","source":"The pharmacogenomics journal","url":"https://pubmed.ncbi.nlm.nih.gov/22231567","citation_count":68,"is_preprint":false},{"pmid":"32311818","id":"PMC_32311818","title":"Serotonin homeostasis in the materno-foetal interface at term: Role of transporters (SERT/SLC6A4 and OCT3/SLC22A3) and monoamine oxidase A (MAO-A) in uptake and degradation of serotonin by human and rat term placenta.","date":"2020","source":"Acta physiologica (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/32311818","citation_count":65,"is_preprint":false},{"pmid":"37319217","id":"PMC_37319217","title":"Induction of astrocytic Slc22a3 regulates sensory processing through histone serotonylation.","date":"2023","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/37319217","citation_count":63,"is_preprint":false},{"pmid":"17010131","id":"PMC_17010131","title":"Association between gene polymorphisms of SLC22A3 and methamphetamine use disorder.","date":"2006","source":"Alcoholism, clinical and experimental research","url":"https://pubmed.ncbi.nlm.nih.gov/17010131","citation_count":42,"is_preprint":false},{"pmid":"20562519","id":"PMC_20562519","title":"Functional analysis of human organic cation transporter OCT3 (SLC22A3) polymorphisms.","date":"2010","source":"Journal of pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/20562519","citation_count":38,"is_preprint":false},{"pmid":"11118898","id":"PMC_11118898","title":"The extraneuronal monoamine transporter Slc22a3/Orct3 co-localizes with the Maoa metabolizing enzyme in mouse placenta.","date":"2001","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/11118898","citation_count":34,"is_preprint":false},{"pmid":"30934600","id":"PMC_30934600","title":"Metformin Pharmacogenetics: Effects of SLC22A1, SLC22A2, and SLC22A3 Polymorphisms on Glycemic Control and HbA1c Levels.","date":"2019","source":"Journal of personalized medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30934600","citation_count":32,"is_preprint":false},{"pmid":"22543277","id":"PMC_22543277","title":"Synchronized activity of organic cation transporter 3 (Oct3/Slc22a3) and multidrug and toxin extrusion 1 (Mate1/Slc47a1) transporter in transplacental passage of MPP+ in rat.","date":"2012","source":"Toxicological sciences : an official journal of the Society of Toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/22543277","citation_count":32,"is_preprint":false},{"pmid":"23562376","id":"PMC_23562376","title":"Transfer of metformin across the rat placenta is mediated by organic cation transporter 3 (OCT3/SLC22A3) and multidrug and toxin extrusion 1 (MATE1/SLC47A1) protein.","date":"2013","source":"Reproductive toxicology (Elmsford, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/23562376","citation_count":31,"is_preprint":false},{"pmid":"27417586","id":"PMC_27417586","title":"Functional Variant in the SLC22A3-LPAL2-LPA Gene Cluster Contributes to the Severity of Coronary Artery Disease.","date":"2016","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/27417586","citation_count":30,"is_preprint":false},{"pmid":"23545524","id":"PMC_23545524","title":"Human organic cation transporters 1 (SLC22A1), 2 (SLC22A2), and 3 (SLC22A3) as disposition pathways for fluoroquinolone antimicrobials.","date":"2013","source":"Antimicrobial agents and chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/23545524","citation_count":29,"is_preprint":false},{"pmid":"30742940","id":"PMC_30742940","title":"Oncogenic PITX2 facilitates tumor cell drug resistance by inverse regulation of hOCT3/SLC22A3 and ABC drug transporters in colon and kidney cancers.","date":"2019","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/30742940","citation_count":27,"is_preprint":false},{"pmid":"30561001","id":"PMC_30561001","title":"Genetic variants in SLC22A3 contribute to the susceptibility to colorectal cancer.","date":"2019","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30561001","citation_count":25,"is_preprint":false},{"pmid":"12768439","id":"PMC_12768439","title":"Genetic variability of the extraneuronal monoamine transporter EMT (SLC22A3).","date":"2003","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12768439","citation_count":22,"is_preprint":false},{"pmid":"30416380","id":"PMC_30416380","title":"Epigenetic alterations of a novel antioxidant gene SLC22A3 predispose susceptible individuals to increased risk of esophageal cancer.","date":"2018","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30416380","citation_count":21,"is_preprint":false},{"pmid":"29088791","id":"PMC_29088791","title":"Upregulated SLC22A3 has a potential for improving survival of patients with head and neck squamous cell carcinoma receiving cisplatin treatment.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29088791","citation_count":20,"is_preprint":false},{"pmid":"23228442","id":"PMC_23228442","title":"Renal tumours in a Tsc1+/- mouse model show epigenetic suppression of organic cation transporters Slc22a1, Slc22a2 and Slc22a3, and do not respond to metformin.","date":"2012","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/23228442","citation_count":20,"is_preprint":false},{"pmid":"30772277","id":"PMC_30772277","title":"SLC22A3 is associated with lipoprotein (a) concentration and cardiovascular disease in familial hypercholesterolemia.","date":"2019","source":"Clinical biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30772277","citation_count":19,"is_preprint":false},{"pmid":"25642596","id":"PMC_25642596","title":"Pet-1 Controls Tetrahydrobiopterin Pathway and Slc22a3 Transporter Genes in Serotonin Neurons.","date":"2015","source":"ACS chemical neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25642596","citation_count":17,"is_preprint":false},{"pmid":"11129104","id":"PMC_11129104","title":"Analysis of the gene structure of the human (SLC22A3) and murine (Slc22a3) extraneuronal monoamine transporter.","date":"2000","source":"Journal of neural transmission (Vienna, Austria : 1996)","url":"https://pubmed.ncbi.nlm.nih.gov/11129104","citation_count":15,"is_preprint":false},{"pmid":"28272475","id":"PMC_28272475","title":"SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28272475","citation_count":14,"is_preprint":false},{"pmid":"30297296","id":"PMC_30297296","title":"Evaluation of the rs3088442 G>A SLC22A3 Gene Polymorphism and the Role of microRNA 147 in Groups of Adult Pakistani Populations With Type 2 Diabetes in Response to Metformin.","date":"2018","source":"Canadian journal of diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/30297296","citation_count":14,"is_preprint":false},{"pmid":"23036009","id":"PMC_23036009","title":"Lack of association between four SNPs in the SLC22A3-LPAL2-LPA gene cluster and coronary artery disease in a Chinese Han population: a case control study.","date":"2012","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/23036009","citation_count":14,"is_preprint":false},{"pmid":"27893421","id":"PMC_27893421","title":"PHACTR1 and SLC22A3 gene polymorphisms are associated with reduced coronary artery disease risk in the male Chinese Han population.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27893421","citation_count":12,"is_preprint":false},{"pmid":"28163738","id":"PMC_28163738","title":"Allele frequency and genotype distribution of a common variant in the 3´-untranslated region of the SLC22A3 gene in patients with type 2 diabetes: Association with response to metformin.","date":"2016","source":"Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28163738","citation_count":10,"is_preprint":false},{"pmid":"34458338","id":"PMC_34458338","title":"Effect of SYTL3-SLC22A3 Variants, Their Haplotypes, and G × E Interactions on Serum Lipid Levels and the Risk of Coronary Artery Disease and Ischaemic Stroke.","date":"2021","source":"Frontiers in cardiovascular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34458338","citation_count":9,"is_preprint":false},{"pmid":"11641723","id":"PMC_11641723","title":"Genetic analysis of the organic cation transporter genes Orct2/Slc22a2 and Orct3/Slc22a3 reduces the critical region for the t haplotype mutant t(w73) to 200 kb.","date":"2001","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/11641723","citation_count":9,"is_preprint":false},{"pmid":"36030241","id":"PMC_36030241","title":"Placental imprinting of SLC22A3 in the IGF2R imprinted domain is conserved in therian mammals.","date":"2022","source":"Epigenetics & chromatin","url":"https://pubmed.ncbi.nlm.nih.gov/36030241","citation_count":8,"is_preprint":false},{"pmid":"34367243","id":"PMC_34367243","title":"SYTL3-SLC22A3 Single-Nucleotide Polymorphisms and Gene-Gene/Environment Interactions on the Risk of Hyperlipidemia.","date":"2021","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34367243","citation_count":7,"is_preprint":false},{"pmid":"35240257","id":"PMC_35240257","title":"The influence of SLC22A3 rs543159 and rs1317652 genetic variants on metformin therapeutic efficacy in newly diagnosed patients with type 2 diabetes mellitus: 25 weeks follow-up study.","date":"2022","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/35240257","citation_count":7,"is_preprint":false},{"pmid":"28743982","id":"PMC_28743982","title":"Oesophageal cancer: RNA editing of SLC22A3 mRNAs: causative relevance to familial ESCC?","date":"2017","source":"Nature reviews. Gastroenterology & hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/28743982","citation_count":6,"is_preprint":false},{"pmid":"36254631","id":"PMC_36254631","title":"Repression of SLC22A3 by the AR-V7/YAP1/TAZ axis in enzalutamide-resistant castration-resistant prostate cancer.","date":"2022","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/36254631","citation_count":5,"is_preprint":false},{"pmid":"37626799","id":"PMC_37626799","title":"SLC22A3 rs2048327 Polymorphism Is Associated with Diabetic Retinopathy in Caucasians with Type 2 Diabetes Mellitus.","date":"2023","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/37626799","citation_count":5,"is_preprint":false},{"pmid":"37948393","id":"PMC_37948393","title":"Effect of MEF2A and SLC22A3-LPAL2-LPA gene polymorphisms on warfarin sensitivity and responsiveness in Jordanian cardiovascular patients.","date":"2023","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/37948393","citation_count":4,"is_preprint":false},{"pmid":"34969749","id":"PMC_34969749","title":"A Single Nucleotide Polymorphism (SNP) in the SLC22A3 Transporter Gene Is Associated With the Severity of Oral Mucositis in Multiple Myeloma Patients Receiving Autologous Stem Cell Transplant Followed by Melphalan Therapy.","date":"2022","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/34969749","citation_count":4,"is_preprint":false},{"pmid":"40426982","id":"PMC_40426982","title":"Molecular Ancestry Across Allelic Variants of SLC22A1, SLC22A2, SLC22A3, ABCB1, CYP2C8, CYP2C9, and CYP2C19 in Mexican-Mestizo DMT2 Patients.","date":"2025","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/40426982","citation_count":4,"is_preprint":false},{"pmid":"37342315","id":"PMC_37342315","title":"The Influence of SLC22A3 Genetic Polymorphisms on Susceptibility to Type 2 Diabetes Mellitus in Chinese Population.","date":"2023","source":"Diabetes, metabolic syndrome and obesity : targets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/37342315","citation_count":2,"is_preprint":false},{"pmid":"33168399","id":"PMC_33168399","title":"Effect of Genetic Polymorphisms of Human SLC22A3 in the 5'-flanking Region on OCT3 Expression and Sebum Levels in Human Skin.","date":"2020","source":"Journal of dermatological science","url":"https://pubmed.ncbi.nlm.nih.gov/33168399","citation_count":2,"is_preprint":false},{"pmid":"27621937","id":"PMC_27621937","title":"A Case-Control Study of the Relationship Between SLC22A3-LPAL2-LPA Gene Cluster Polymorphism and Coronary Artery Disease in the Han Chinese Population.","date":"2016","source":"Iranian Red Crescent medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/27621937","citation_count":2,"is_preprint":false},{"pmid":"36909526","id":"PMC_36909526","title":"Activity-dependent induction of astrocytic Slc22a3 regulates sensory processing through histone serotonylation.","date":"2023","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/36909526","citation_count":1,"is_preprint":false},{"pmid":"38896441","id":"PMC_38896441","title":"A Polynesian-specific SLC22A3 variant associates with low plasma lipoprotein(a) concentrations independent of apo(a) isoform size in males.","date":"2024","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/38896441","citation_count":1,"is_preprint":false},{"pmid":"22741436","id":"PMC_22741436","title":"[Association of prostate cancer with PDLIM5, SLC22A3 and NKX3-1 in Chinese men].","date":"2012","source":"Zhonghua nan ke xue = National journal of andrology","url":"https://pubmed.ncbi.nlm.nih.gov/22741436","citation_count":1,"is_preprint":false},{"pmid":"40570980","id":"PMC_40570980","title":"Unraveling the protective role of m6A methylation in SLC22A3 expression for breast Cancer intervention.","date":"2025","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/40570980","citation_count":0,"is_preprint":false},{"pmid":"37924453","id":"PMC_37924453","title":"Genetic preservation of SLC22A3 in the Admixed and Xhosa populations living in the Western Cape.","date":"2023","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/37924453","citation_count":0,"is_preprint":false},{"pmid":"41833108","id":"PMC_41833108","title":"SLC22A3 deficiency leads to cognitive impairment through the cardio-neuroinflammatory axis mediated HA/H1R/NLRP3 pathway in heart failure mice.","date":"2026","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/41833108","citation_count":0,"is_preprint":false},{"pmid":"41011206","id":"PMC_41011206","title":"Pharmacogenetics and Molecular Ancestry of SLC22A1, SLC22A2, SLC22A3, ABCB1, CYP2C8, CYP2C9, and CYP2C19 in Ecuadorian Subjects with Type 2 Diabetes Mellitus.","date":"2025","source":"Pharmaceuticals (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/41011206","citation_count":0,"is_preprint":false},{"pmid":"41806154","id":"PMC_41806154","title":"Comprehensive Analysis of Bulk RNA-seq, Machine Learning, Mendelian Randomization, and Single-Cell Sequencing Unravels SLC22A3 as a Solute Carrier Superfamily-Associated Biomarker in Atherosclerosis.","date":"2026","source":"Journal of cardiovascular translational research","url":"https://pubmed.ncbi.nlm.nih.gov/41806154","citation_count":0,"is_preprint":false},{"pmid":"42250222","id":"PMC_42250222","title":"SLC22A3/OCT3 drives serotonin-mediated stemness in pancreatic cancer.","date":"2026","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/42250222","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.10.08.25337553","title":"Genetic Architecture of Placental Efficiency for Term Infants: Evidence from Monoaminergic Pathways and Placental Tissue Expression in the Norwegian Mother, Father and Child Cohort Study (MoBa)","date":"2025-10-09","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.08.25337553","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.10.13.25337858","title":"The tissue-specific effects of glucose-lowering drug targets on aging mediated through DNA methylation: a multi-omics genetic study","date":"2025-10-14","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.13.25337858","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":34069,"output_tokens":6143,"usd":0.097176,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14898,"output_tokens":4407,"usd":0.092332,"stage2_stop_reason":"end_turn"},"total_usd":0.189508,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"Genetic knockout of mouse Orct3/Slc22a3 demonstrated that this transporter is the principal component of the extraneuronal uptake-2 system in the adult heart, as measured by a 72% reduction in intravenously administered [3H]MPP+ accumulation in hearts of null mice. Additionally, Orct3 was identified as functioning at the fetoplacental interface, with a threefold-reduced MPP+ accumulation in homozygous mutant embryos but not in placentas.\",\n      \"method\": \"Homologous recombination knockout mouse model; isotopic [3H]MPP+ uptake assays in vivo\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vivo loss-of-function with quantitative substrate accumulation assays, replicated across sexes and developmental stages\",\n      \"pmids\": [\"11390648\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"SLC22A3 was cloned and mapped to human chromosome 6q26-q27 in a conserved cluster with SLC22A1 and SLC22A2. Expression was detected in placenta (first-trimester and term), skeletal muscle, prostate, aorta, liver, fetal lung, salivary gland, and adrenal gland.\",\n      \"method\": \"cDNA cloning from EST clones; Northern blot expression analysis; somatic cell hybrid panel mapping; YAC clone mapping\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct cloning and localization by multiple methods in a single study\",\n      \"pmids\": [\"9933568\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Slc22a3/Orct3 co-localizes with the monoamine-metabolizing enzyme Maoa in the labyrinth layer of mouse placenta, establishing that these two components of monoamine clearance are co-expressed at the same site, distinct from neuronal transporter expression patterns.\",\n      \"method\": \"RNA blot analysis; in situ hybridization in mouse embryo placenta sections\",\n      \"journal\": \"Mechanisms of development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — direct localization by two orthogonal methods (RNA blot + ISH) in a single lab\",\n      \"pmids\": [\"11118898\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Imprinted silencing of Slc22a3 (paternal allele) does not require transcriptional overlap between Igf2r and the non-coding Air RNA; silencing is maintained even when the Igf2r promoter is replaced by a heterologous promoter or deleted entirely.\",\n      \"method\": \"Genetic epistasis using knock-in mice with replaced or deleted Igf2r promoter; allele-specific expression analysis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — genetic epistasis with multiple allelic combinations tested, mechanistically defining cis-regulatory requirements for imprinting\",\n      \"pmids\": [\"12853484\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"hOCT3 (SLC22A3) mediates uptake of organic cations with substrate selectivity distinct from hOCT1 and hOCT2: famotidine is a potent inhibitor of hOCT3 (IC50 = 6.7 µM) while ranitidine is a weak inhibitor (IC50 = 290 µM); no stimulation of [3H]ranitidine uptake was detected in hOCT3-expressing oocytes, indicating ranitidine is not an hOCT3 substrate.\",\n      \"method\": \"Xenopus laevis oocyte expression system; isotopic uptake inhibition assays; trans-stimulation; electrophysiology\",\n      \"journal\": \"The Journal of pharmacology and experimental therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted transport in heterologous expression system with multiple orthogonal methods (uptake inhibition, trans-stimulation, electrophysiology)\",\n      \"pmids\": [\"16141367\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"hOCT3/SLC22A3 transports oxaliplatin (but not cisplatin) into colorectal cancer cells, mediating cytotoxicity: transfection of hOCT3 into SW480 cells increased platinum accumulation and LDH release after oxaliplatin treatment; colorectal cancer cell lines with high endogenous hOCT3 accumulated more platinum and showed greater cytotoxicity.\",\n      \"method\": \"cDNA transfection; LDH release cytotoxicity assay; ICP-MS platinum accumulation measurement; qRT-PCR mRNA quantification\",\n      \"journal\": \"Drug metabolism and disposition\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — functional reconstitution by transfection plus orthogonal cytotoxicity and platinum accumulation assays in multiple cell lines\",\n      \"pmids\": [\"18710896\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"OCT3/SLC22A3 protein is localized to the basolateral membrane of hepatocytes, and metformin is confirmed as an OCT3 substrate by isotopic uptake studies in transfected cells.\",\n      \"method\": \"Immunofluorescence microscopy for subcellular localization; isotopic uptake assays in transfected cells\",\n      \"journal\": \"Hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization by immunofluorescence plus functional substrate confirmation in transfected cells, single lab\",\n      \"pmids\": [\"19591196\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"OCT3/SLC22A3 plays a role in metformin's pharmacological action: OCT3 is expressed on the plasma membrane of skeletal muscle and liver (metformin target tissues); OCT inhibitor cimetidine and OCT3-specific shRNA significantly reduced metformin-induced AMP-activated protein kinase activation. Three missense variants (T44M, T400I, V423F) showed altered substrate specificity for metformin and catecholamines in functional assays.\",\n      \"method\": \"Quantitative PCR; immunostaining; isotopic uptake assays in transfected cells; shRNA knockdown; AMPK phosphorylation assay; structural modeling\",\n      \"journal\": \"Pharmacogenetics and genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple orthogonal methods (shRNA KD, pharmacologic inhibition, isotopic uptake, AMPK assay) converging on same conclusion in one study\",\n      \"pmids\": [\"20859243\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Three OCT3 missense variants (A116S, T400I, A439V) show reduced uptake of both [3H]histamine and [3H]MPP+ despite normal plasma membrane localization, indicating these variants impair transport activity without affecting trafficking.\",\n      \"method\": \"Transient transfection; isotopic uptake assays; immunostaining for protein localization\",\n      \"journal\": \"Journal of pharmacological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — functional isotopic uptake assay with localization control, single lab, single paper\",\n      \"pmids\": [\"20562519\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The SLC22A3 promoter is regulated by epigenetic methylation (associated with reduced expression in prostate cancer) and by genetic variants: haplotypes containing g.-81G>delGA and g.-2G>A show increased luciferase reporter activity and stronger transcription factor binding affinity; the g.-2A allele correlates with higher OCT3 mRNA in liver.\",\n      \"method\": \"Luciferase reporter assay; electrophoretic mobility shift assay; bisulfite sequencing; mRNA expression analysis in human liver samples\",\n      \"journal\": \"The pharmacogenomics journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple functional assays (reporter, EMSA, methylation analysis, expression correlation) in a single lab\",\n      \"pmids\": [\"22231567\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Oct3/Slc22a3 is localized on the basolateral (fetus-facing) side of rat placental trophoblast, and together with apically-localized Mate1/Slc47a1, forms an efficient transplacental eliminatory pathway: Oct3 takes up MPP+ from fetal circulation into the placenta, while Mate1 effluxes it to the maternal side, transporting substrate against a concentration gradient.\",\n      \"method\": \"qRT-PCR; Western blot; immunohistochemistry; in situ dually perfused rat term placenta (open- and closed-circuit); [3H]MPP+ transport assays\",\n      \"journal\": \"Toxicological sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct functional localization plus reconstituted transplacental transport with pharmacologic inhibition, multiple experimental configurations\",\n      \"pmids\": [\"22543277\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"OCT3/SLC22A3 mediates the fetal-to-maternal transplacental transfer of metformin in rat placenta in a concentration-dependent manner; this transport is completely inhibited by MPP+ and is driven by opposing H+ gradient for MATE1-mediated efflux, confirming functional coupling of OCT3 (basolateral uptake) and MATE1 (apical efflux) in metformin secretion.\",\n      \"method\": \"Dually perfused rat term placenta model; pharmacologic inhibition with MPP+; pH gradient manipulation\",\n      \"journal\": \"Reproductive toxicology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct functional reconstitution in intact perfused placenta with pharmacologic dissection, builds on prior work by same group\",\n      \"pmids\": [\"23562376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The transcription factor Pet-1 controls expression of Slc22a3 in serotonin neurons: comparative microarray profiling of flow-sorted Pet-1-/- versus wild-type 5-HT neurons showed loss of Slc22a3 expression; in situ hybridization confirmed that virtually all 5-HT neurons in the dorsal raphe depend on Pet-1 for Slc22a3 expression, establishing Pet-1 as a transcriptional regulator coordinating both 5-HT synthesis and reuptake genes.\",\n      \"method\": \"Comparative microarray of flow-sorted YFP+ neurons; in situ hybridization\",\n      \"journal\": \"ACS chemical neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — microarray plus orthogonal ISH validation, loss-of-function genetic model, single lab\",\n      \"pmids\": [\"25642596\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"A-to-I RNA editing of SLC22A3 mRNA by ADAR2 results in reduced SLC22A3 expression in non-tumor esophageal tissues. SLC22A3 acts as a metastasis suppressor: it directly associates with α-actinin-4 (ACTN4), and loss of this interaction increases ACTN4 actin-binding activity, facilitating cell invasion and filopodia formation.\",\n      \"method\": \"Co-immunoprecipitation (SLC22A3–ACTN4 interaction); actin-binding activity assay; cell invasion assays; filopodia formation imaging; RNA editing quantification; shRNA knockdown\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct binding partner identified by Co-IP, functional consequence demonstrated by actin-binding and invasion assays with mechanistic pathway defined\",\n      \"pmids\": [\"28533408\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Oncogenic PITX2 transcription factor represses SLC22A3/hOCT3 expression: ChIP-qPCR showed PITX2 binds the hOCT3/SLC22A3 promoter in colon and renal cancer cells; PITX2 siRNA knockdown increased hOCT3/SLC22A3 expression and activity and reverted vincristine resistance, while heterologous PITX2 overexpression suppressed hOCT3/SLC22A3 and enhanced drug resistance. PITX2A and PITX2C isoforms were most effective.\",\n      \"method\": \"ChIP-qPCR; siRNA knockdown; heterologous overexpression; drug resistance/viability assays; transporter activity assays\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — ChIP-qPCR for direct promoter binding plus bidirectional functional manipulation (siRNA KD and overexpression) with functional consequence\",\n      \"pmids\": [\"30742940\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"OCT3/SLC22A3 is localized on the fetus-facing membrane of syncytiotrophoblast in human and rat term placenta, where it massively takes up serotonin from fetal circulation in a concentration-dependent and OCT3 blocker-inhibitable manner, forming a protective mechanism against local vasoconstriction with MAO-A. Glucocorticoids and antidepressants can inhibit this system.\",\n      \"method\": \"Dually perfused rat term placenta; placental membrane vesicles from human term placenta; pharmacologic inhibition with OCT3 blockers (glucocorticoids, pharmaceuticals); concentration-response analysis\",\n      \"journal\": \"Acta physiologica\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct functional transport assays in intact perfused organ and isolated membrane vesicles with pharmacologic dissection, two species\",\n      \"pmids\": [\"32311818\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"The SLC22A3 promoter variant -1603G>A reduces p53 binding to the promoter region, leading to decreased SLC22A3 mRNA expression in human skin; homozygous -1603A/A individuals have significantly lower SLC22A3 mRNA levels and lower squalene levels in skin, linking OCT3 to sebaceous gland function.\",\n      \"method\": \"Immunohistochemistry; luciferase reporter assay; ChIP; electrophoretic mobility shift assay (EMSA); mRNA expression analysis; in vivo sebum/squalene measurement\",\n      \"journal\": \"Journal of dermatological science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple functional assays (reporter, ChIP, EMSA) plus in vivo phenotypic correlation, single lab\",\n      \"pmids\": [\"33168399\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"AR-V7/YAP1/TAZ axis represses SLC22A3 in enzalutamide-resistant castration-resistant prostate cancer: YAP1/TAZ hyperactivated by AR full-length or AR-V7 interacts with DNMT1 to methylate and silence the SLC22A3 promoter; this repression was demonstrated in ENZ-resistant C4-2B MDVR cells.\",\n      \"method\": \"Co-immunoprecipitation (YAP1/TAZ–DNMT1 interaction); siRNA knockdown; promoter methylation analysis; Western blot; immunostaining in patient tissues\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — Co-IP for complex identification plus functional methylation evidence, single lab, single paper\",\n      \"pmids\": [\"36254631\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Neuronal activity induces Slc22a3 expression in astrocytes; loss of astrocytic Slc22a3 reduces intracellular serotonin levels, leading to decreased histone serotonylation in astrocytes, reduced GABA biosynthetic gene expression, reduced GABA release, and olfactory sensory processing deficits in mice.\",\n      \"method\": \"Activity-inducible gene expression profiling; conditional knockout (loss-of-function) with behavioral phenotyping; serotonin quantification; histone serotonylation assay; GABA release measurement; olfactory bulb circuit analysis\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean conditional KO with specific cellular phenotype, multiple orthogonal downstream measurements (histone serotonylation, GABA biosynthesis, GABA release, behavioral), peer-reviewed in high-impact journal\",\n      \"pmids\": [\"37319217\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Tammar wallaby SLC22A3 is imprinted (paternal allele silenced) specifically in placental tissue, with the protein localized to the endodermal cell layer where nutrient trafficking occurs; promoter lacks DNA methylation, indicating silencing is not via direct DMR at the SLC22A3 promoter as in mouse.\",\n      \"method\": \"Allele-specific expression analysis; bisulfite sequencing; immunofluorescence localization in tammar wallaby placenta\",\n      \"journal\": \"Epigenetics & chromatin\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — allele-specific expression plus methylation analysis and direct protein localization, mechanistically defining imprinting mechanism in a marsupial\",\n      \"pmids\": [\"36030241\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"SLC22A3 suppression reduces tumor-related cellular phenotypes (proliferation, migration, invasion) in prostate cancer cells, implicating SLC22A3 in prostate cancer pathogenesis through functional cellular assays.\",\n      \"method\": \"siRNA knockdown of SLC22A3 in prostate cancer cell lines; assays for proliferation, migration, and invasion\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — functional KD phenotype in cell lines, single lab, abstract does not provide full mechanistic detail\",\n      \"pmids\": [\"22730461\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SLC22A3 acts as an antioxidant gene in normal esophageal epithelial cells: deregulation of SLC22A3 (by promoter hypermethylation) facilitates heat stress-induced oxidative DNA damage and formation of γ-H2AX foci.\",\n      \"method\": \"Bisulfite sequencing for promoter methylation; γ-H2AX foci immunofluorescence after heat stress; functional overexpression/knockdown\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct functional consequence of SLC22A3 loss on oxidative DNA damage, single lab, limited mechanistic detail in abstract\",\n      \"pmids\": [\"30416380\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"SLC22A3/OCT3 regulates pancreatic cancer stem cell (CSC) stemness through serotonin transport: SLC22A3 is upregulated in CSC-enriched populations; its silencing in 2D cultures and 3D organoid models reduces stemness features; serotonin transport by SLC22A3 enhances stemness via downstream histone modifications.\",\n      \"method\": \"siRNA silencing; 2D cell culture and 3D organoid models; stemness assays; histone modification analysis\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function in 2D and 3D models with downstream histone modification readout, single lab, single paper\",\n      \"pmids\": [\"42250222\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"Cardiac SLC22A3 deficiency in heart failure leads to elevated peripheral and brain histamine levels; cardiac-specific SLC22A3 overexpression reduces histamine accumulation, preserves blood-brain barrier integrity, and improves cognitive performance. Mechanistically, elevated histamine activates hippocampal microglial H1R/NLRP3 inflammasome signaling to drive neuroinflammation; blocking H1R or NLRP3 in hippocampus rescues heart failure-induced cognitive impairment.\",\n      \"method\": \"Mouse MI model; cardiac-specific SLC22A3 overexpression; hippocampal-specific H1R knockdown; NLRP3 knockout mice; BV2 cell assays; Morris water maze; immunofluorescence; Western blot\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple genetic manipulations (OE, KD, KO) with converging mechanistic pathway, single lab\",\n      \"pmids\": [\"41833108\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SLC22A3 (OCT3) is a polyspecific organic cation transporter localized to basolateral membranes of hepatocytes, the fetus-facing membrane of placental syncytiotrophoblast, and plasma membranes of skeletal muscle, heart, and other tissues, where it mediates electrogenic, facilitated uptake of monoamines (noradrenaline, dopamine, serotonin, histamine), cationic drugs (metformin, oxaliplatin, MPP+), and other organic cations; in the heart it is the principal component of the extraneuronal uptake-2 system; in placenta it forms a vectorial transport axis with MATE1 to protect the fetus from xenobiotics and regulate serotonin homeostasis; in astrocytes, activity-induced Slc22a3 expression drives serotonin uptake, histone serotonylation, GABA release, and sensory processing; in cancer cells it acts as a metastasis suppressor by binding α-actinin-4 (ACTN4) and is epigenetically silenced by promoter methylation, PITX2-mediated transcriptional repression, or AR-V7/YAP1/TAZ–DNMT1 complexes; paternal allele silencing in placenta is controlled in cis by the Air non-coding RNA independently of Igf2r transcriptional overlap; and genetic variants in its coding and promoter regions alter substrate transport kinetics and drug response.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"SLC22A3 (OCT3) is a polyspecific, electrogenic organic cation transporter that mediates facilitated uptake of monoamines and cationic drugs across plasma membranes in heart, liver, placenta, skeletal muscle, and the nervous system, and constitutes the principal extraneuronal uptake-2 system of the adult heart [#0, #4]. Its substrate spectrum—distinct from the related OCT1/OCT2 transporters with which it clusters on chromosome 6q26-q27—includes MPP+, histamine, serotonin, the cytotoxic platinum drug oxaliplatin, and metformin, the last of which it carries into target tissues to drive AMPK activation [#1, #4, #5, #6, #7]. In the placenta OCT3 resides on the fetus-facing (basolateral) membrane of the trophoblast and operates as the uptake arm of a vectorial elimination axis with the apical efflux transporter MATE1, clearing organic cations and serotonin from the fetal circulation; co-expression with the monoamine-metabolizing enzyme MAO-A makes this a combined detoxification and serotonin-homeostasis system [#2, #10, #11, #15]. The gene is subject to genomic imprinting with paternal-allele silencing in placenta, maintained in cis independently of Igf2r/Air transcriptional overlap [#3]. In the brain, activity-induced astrocytic SLC22A3 imports serotonin to fuel histone serotonylation, GABA biosynthesis, and sensory processing, while cardiac OCT3 loss elevates histamine to drive H1R/NLRP3-dependent neuroinflammation and cognitive impairment [#18, #23]. In epithelial cancers SLC22A3 functions as a metastasis suppressor by binding α-actinin-4 (ACTN4) to restrain its actin-binding and invasive activity, and is silenced through promoter hypermethylation, PITX2-mediated repression, and an AR-V7/YAP1/TAZ–DNMT1 axis [#13, #14, #17, #20]. Coding and promoter variants of SLC22A3 alter transport kinetics, transcription-factor binding, and downstream drug response and tissue phenotypes [#7, #8, #9, #16].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Establishing the gene's identity, chromosomal location, and tissue distribution defined SLC22A3 as a third member of an organic-cation transporter cluster with broad somatic expression.\",\n      \"evidence\": \"cDNA cloning, Northern blot, and somatic-cell-hybrid/YAC mapping\",\n      \"pmids\": [\"9933568\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No transport function demonstrated in this study\", \"Subcellular localization not resolved\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Knockout of the mouse ortholog answered whether OCT3 carries a defined physiological transport burden in vivo, identifying it as the principal extraneuronal uptake-2 system of the heart and a fetoplacental transporter.\",\n      \"evidence\": \"Homologous-recombination knockout mouse with in vivo [3H]MPP+ accumulation assays; placental ISH co-localization with Maoa\",\n      \"pmids\": [\"11390648\", \"11118898\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous physiological substrate(s) in heart not pinned to a single monoamine\", \"Mechanism of membrane targeting not addressed\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Genetic epistasis defined the cis-regulatory logic of SLC22A3 imprinting, showing paternal silencing does not require Igf2r/Air transcriptional overlap.\",\n      \"evidence\": \"Knock-in mice with replaced or deleted Igf2r promoter and allele-specific expression analysis\",\n      \"pmids\": [\"12853484\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The Air-dependent silencing mechanism (chromatin vs. RNA-mediated) not fully resolved\", \"Does not address human imprinting status\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Substrate-selectivity and drug-transport studies established OCT3 as a distinct organic-cation carrier handling specific therapeutics including oxaliplatin and famotidine.\",\n      \"evidence\": \"Xenopus oocyte uptake/electrophysiology and cancer-cell transfection with ICP-MS platinum accumulation and cytotoxicity assays\",\n      \"pmids\": [\"16141367\", \"18710896\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of substrate selectivity not determined\", \"In vivo relevance of oxaliplatin transport not tested\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Linking OCT3 to metformin action and characterizing coding variants connected transport activity to pharmacological outcome and inter-individual variation.\",\n      \"evidence\": \"shRNA knockdown, pharmacologic inhibition, isotopic uptake, AMPK assays, and variant uptake assays with localization controls\",\n      \"pmids\": [\"20859243\", \"20562519\", \"19591196\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether variants alter clinical metformin response not established\", \"Hepatic basolateral targeting mechanism unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Dual perfusion of placenta and identification of neuronal/cancer regulators showed OCT3 forms a vectorial transplacental elimination axis with MATE1 and is transcriptionally controlled in specialized cell types.\",\n      \"evidence\": \"Dually perfused rat placenta with pharmacologic dissection; Pet-1 knockout microarray/ISH in 5-HT neurons; promoter reporter/EMSA/methylation analyses; prostate cancer siRNA phenotyping\",\n      \"pmids\": [\"22543277\", \"22231567\", \"22730461\", \"25642596\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether placental coupling operates identically in human in vivo not fully proven\", \"Direct transcription factors driving promoter haplotype effects not all identified\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstration that OCT3 carries metformin fetal-to-maternal against gradient confirmed functional coupling of basolateral OCT3 uptake with apical MATE1 efflux.\",\n      \"evidence\": \"Dually perfused rat placenta with MPP+ inhibition and pH-gradient manipulation\",\n      \"pmids\": [\"23562376\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution to human fetal drug exposure unmeasured\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identification of the SLC22A3–ACTN4 interaction provided a transport-independent mechanism for its metastasis-suppressor function.\",\n      \"evidence\": \"Co-IP, actin-binding and invasion/filopodia assays, RNA-editing quantification, and shRNA knockdown in esophageal cancer\",\n      \"pmids\": [\"28533408\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ACTN4 binding requires transport activity unresolved\", \"Structural details of the interaction not defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"PITX2 was defined as a direct transcriptional repressor of SLC22A3 governing chemoresistance.\",\n      \"evidence\": \"ChIP-qPCR, bidirectional siRNA/overexpression, and drug-resistance/transporter-activity assays in colon and renal cancer cells\",\n      \"pmids\": [\"30742940\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cofactors recruited by PITX2 at the promoter not identified\", \"Relationship to methylation-based silencing not integrated\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Placental serotonin-clearance and skin-phenotype studies extended OCT3's physiological roles to fetal serotonin homeostasis and sebaceous gland function, with promoter p53 binding as a regulatory input.\",\n      \"evidence\": \"Dually perfused rat placenta and human membrane vesicles with pharmacologic inhibition; promoter ChIP/EMSA/reporter and in vivo squalene measurement\",\n      \"pmids\": [\"32311818\", \"33168399\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Causal link between OCT3 serotonin uptake and placental vascular outcomes not directly demonstrated in human pregnancy\", \"Skin phenotype based on variant correlation\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Comparative imprinting and additional cancer-silencing studies showed the imprinting mechanism differs across mammals and that an AR-V7/YAP1/TAZ–DNMT1 axis methylates SLC22A3 in resistant prostate cancer.\",\n      \"evidence\": \"Marsupial allele-specific expression/bisulfite/localization; Co-IP, siRNA, and promoter methylation analysis in enzalutamide-resistant prostate cancer cells\",\n      \"pmids\": [\"36030241\", \"36254631\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Marsupial silencing mechanism without promoter DMR not mechanistically defined\", \"AR-V7/YAP1/TAZ–DNMT1 model rests on single-lab Co-IP\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Astrocytic conditional knockout connected OCT3 serotonin import to histone serotonylation and GABAergic signaling, establishing a role in sensory circuit function.\",\n      \"evidence\": \"Activity-inducible profiling, conditional KO with behavioral phenotyping, serotonin/serotonylation and GABA-release measurements in olfactory bulb\",\n      \"pmids\": [\"37319217\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this pathway operates in human brain unknown\", \"Generality beyond olfactory circuitry untested\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Cardiac and cancer-stem-cell studies tied OCT3 substrate transport to histamine-driven neuroinflammation and serotonin-dependent stemness via histone modifications.\",\n      \"evidence\": \"Mouse MI model with cardiac OCT3 overexpression and hippocampal H1R knockdown/NLRP3 KO; siRNA silencing in 2D and 3D pancreatic cancer organoid models with histone-modification readouts\",\n      \"pmids\": [\"41833108\", \"42250222\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Heart-to-brain histamine axis demonstrated only in mouse\", \"Direct histone-modification enzymology downstream of OCT3 transport not defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How OCT3's transport activity is mechanistically coupled to its non-transport scaffolding/suppressor roles, and how a single transporter's substrate flux is translated into chromatin (serotonylation, histone-modification) outputs across tissues, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structure of human OCT3 reported in the corpus\", \"Mechanism linking cation uptake to histone serotonylation enzymology undefined\", \"Whether ACTN4 binding and transport are separable functions unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [0, 4, 5, 6, 10, 15]},\n      {\"term_id\": \"GO:0140104\", \"supporting_discovery_ids\": [4, 6, 15]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [13]},\n      {\"term_id\": \"GO:0016209\", \"supporting_discovery_ids\": [21]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [6, 7, 8, 10, 15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [0, 4, 10, 11, 15]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [13, 14, 17, 20]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [12, 18]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"ACTN4\", \"SLC47A1\", \"MATEinteraction\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}